Skip to main content

Table 4 Survey diagnosed migraine patients by MIDAS grade with prescription orders 12-months before their completed survey

From: Combining patient reported outcomes and EHR data to understand population level treatment needs: correcting for selection bias in the migraine signature study

Prescription medication orders

No corrections

Corrected for sampling weight only from Strata A–D*

Corrected for sampling weight and response bias from Strata A–D*

MIDAS I–II

N = 729% (SE)

MIDAS III–IV

N = 791% (SE)

MIDAS I–II

N = 729% (SE)

MIDAS III–IV

N = 791% (SE)

MIDAS I–II

N = 729% (SE)

MIDAS III–IV

N = 791% (SE)

Acute treatment orders 12 months before the completed survey

All acute treatment prescriptions

28.6% (2.0%)

37.7% (1.8%)

32.3% (0.2%)

37.3% (0.2%)

24.8% (0.06%)

26.6%†† (0.06%)

Non-narcotic analgesics**

 1–2 orders

1.4% (0.5%)

2.5% (0.6%)

1.2% (0.4%)

1.5% (0.04%)

2.5% (0.02%)

1.0%††, ††† (0.01%)

 3 + orders

0.4% (0.3%)

1.3% (0.4%)

0.3% (0.02%)

1.4% (0.04%)

0.3% (0.01%)

1.1%††† (0.01%)

Narcotic analgesics**

 1–2 orders

2.8% (0.7%)

3.8% (0.7%)

2.5% (0.06%)

3.7% (0.07%)

1.5% (0.02%)

2.7%††,††† (0.02%)

 3 + orders

1.4% (0.5%)

3.6% (0.7%)

1.5% (0.04%)

2.8% (0.06%)

1.1% (0.01%)

2.2%††,††† (0.02%)

Triptans**

      

 1–2 orders

20.3% (1.8%)

21.5% (1.6%)

23.4% (0.2%)

23.5% (0.2%)

17.0% (0.05%)

18.1%††,††† (0.05%)

 3 + orders

4.3% (0.9%)

8.7% (1.1%)

5.3% (0.08%)

8.3% (0.1%)

3.1% (0.02%)

6.1%††,††† (0.03%)

Other migraine-specific treatments**

 1–2 orders

0.6% (0.3%)

4.1% (0.7%)

0.6% (0.03%)

3.1% (0.06%)

0.2% (0.01%)

1.4%††,††† (0.02%)

 3 + orders

0.2% (0.2%)

0.6% (0.3%)

0.2% (0.02%)

0.5% (0.03%)

0.06% (0.005%)

0.2%††,††† (0.01%)

Preventive treatment orders 12-months before the completed survey

All preventive treatments prescriptions

11.8% (1.4%)

21.6% (1.6%)

12.0% (0.1%)

17.7% (0.1%)

8.1% (0.04%)

12.0%†† (0.04%)

Beta blockers, any

 1–2 orders

2.8% (0.7%)

3.8% (0.7%)

2.7% (0.06%)

3.7% (0.07%)

2.4% (0.02%)

2.7%†† (0.02%)

 3 + orders

0.2% (0.2%)

1.6% (0.5%)

0.3% (0.02%)

1.0% (0.04%)

0.2% (0.01%)

0.5%†† (0.01%)

Calcium channel blockers, any

 1–2 orders

1.6% (0.5%)

1.5% (0.5%)

1.3% (0.04%)

1.0% (0.04%)

0.6% (0.01%)

0.6%†† (0.01%)

 3 + orders

0.2% (0.2%)

0.3% (0.2%)

0.1% (0.01%)

0.4% (0.02%)

0.03% (0.002%)

0.2% (0.01%)

Antidepressants, any

 1–2 orders

3.6% (0.8%)

5.1% (0.8%)

4.1% (0.07%)

4.7% (0.08%)

2.3% (0.02%)

2.6%†† (0.02%)

 3 + orders

1.0% (0.4%)

2.2% (0.6%)

1.0% (0.04%)

1.7% (0.05%)

0.5% (0.01%)

1.0%††,††† (0.01%)

Anticonvulsants, any

 1–2 orders

3.7% (0.8%)

7.4% (1.0%)

3.5% (0.07%)

5.4% (0.08%)

2.7% (0.02%)

3.9%††,††† (0.03%)

 3 + orders

1.4% (0.5%)

3.2% (0.7%)

1.3% (0.04%)

2.1% (0.05%)

0.6% (0.01%)

1.9%††,††† (0.02%)

Onabotulinumtoxin A, any

 1–2 orders

0.8% (0.4%)

2.6% (0.6%)

0.7% (0.03%)

1.8% (0.05%)

0.3% (0.01%)

1.0%†† (0.03%)

 3 + orders

0.2% (0.2%)

0%

0.2% (0.02%)

0%

0.1% (0.002%)

0%

  1. The bold is used to distinguish the total for acute and preventive treatment proportions from the proportions for specific classes of acute and preventive medications
  2. *Also adjusted for strata distribution
  3. Statistically significant comparing fully adjusted versus no correction for MIDAS I–II
  4. ††Statistically significant comparing fully adjusted versus no correction for MIDAS III–V
  5. †††Statistically significant comparing fully adjusted MIDAS I–II versus MIDAS III–V
  6. **Multiple comparison: statistically significant comparing fully adjusted MIDAS I–II versus MIDAS III–V